Omeros (OMER) Stock Forecast and Price Target (2026)
Last updated July 2026
Short answer
There is no meaningful analyst consensus for Omeros (OMER): too few analysts publish estimates on it for an average target to mean anything. That is normal for smaller and newer companies and says nothing about the business. What is left is the setup, the drivers and the risks below, which you assess yourself rather than starting from someone else's model. Walnut is not an investment adviser.
Why OMER has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with OMER. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.
Screens that show Omeros at roughly 100 times sales are reading a trailing window that mostly predates the product: YARTEMLEA only began selling in January 2026. Against the second-quarter net revenue run rate of about $114 million annualized, the same market value is closer to nine times sales, which is an ordinary multiple for a rare-disease launch and a demanding one if the ramp stalls. Reported profitability is also flattered by one-time items, since first-half net income of about $69.3 million includes the Novo Nordisk transaction rather than recurring operations.
What could move OMER from here
In short: the drivers cited most often are The YARTEMLEA launch curve, A repaired balance sheet, not a raised one, The OMIDRIA royalty tail and the Novo milestones. The risk cited most often against it is concentration is the first-order risk: one drug, one indication, one country generating essentially all product revenue, with a patient population measured in the low thousands per year.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the OMER is it a buy page. This page deliberately stops at the numbers.
Investing in Omeros with AI
Connect the broker you already use and ask Walnut's AI how OMER fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the price target for Omeros (OMER)?
+
There is no meaningful consensus price target for OMER, because too few analysts publish on it. That is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does OMER have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean you are doing the analysis yourself rather than starting from someone else's model.
What could move OMER?
+
The drivers and the risks are laid out on this page and in more depth on the OMER "is it a buy" page. Without analyst estimates to anchor to, the honest framing is scenarios rather than a number.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a August 2026 data pull of published third-party research, are approximate, and change constantly. Verify current figures with your broker before acting on them.